Contract Development & Manufacturing Organizations (CDMOs): Cold Chain, Cell & Gene, Biologic Fill-Finish in 2026

TL;DR

Contract development and manufacturing organizations (CDMOs) are the outsourced factory layer of the pharmaceutical industry. Published 2026 global CDMO market estimates cluster in a $230-275B range growing at 8-10% CAGR through the early 2030s, with biologics, cell and gene therapy (CGT), and sterile fill-finish segments expanding at 15-19%. The market is dominated by 5-10 mega-CDMOs: Lonza, Catalent (acquired by Novo Holdings for $16.5B in December 2024), Samsung Biologics, Thermo Fisher Patheon, WuXi Biologics, and Fujifilm Diosynth. More than 80% of biotechs outsource at least part of manufacturing. The BIOSECURE Act, signed into law December 2025 as part of the FY2026 NDAA, has triggered a multi-year reshoring wave that is tightening non-Chinese fill-finish and viral vector capacity at the same time that GLP-1 injectable demand is absorbing sterile capacity across Novo Nordisk, Lilly, and their CDMO partners. Launch teams planning 2027-2030 commercial supply must book capacity now.

CDMO Market in Brief

Market Definition

A CDMO (contract development and manufacturing organization) is a vendor that manufactures pharmaceutical products on behalf of a drug owner. CDMOs span the value chain from API synthesis through drug substance, drug product, fill-finish, packaging, and analytical release. CMO (contract manufacturing organization) is the narrower legacy term for manufacturing-only vendors; most modern players offer integrated development plus manufacturing and market themselves as CDMOs.

Global Market Size (2026)

Published 2026 global CDMO market estimates vary widely based on scope:

Source	2026 Estimate	Methodology Scope
Precedence Research	~$275B	Broad: includes API, DS, DP, fill-finish, packaging, clinical supply
Towards Healthcare	~$273B	Broad; projects $337B by 2035
Fortune Business Insights	~$236B	Mid-scope
Mordor Intelligence	~$211B	Core CDMO services
MarketsandMarkets	~$180B	Narrow: contract manufacturing only

Consensus CAGR across sources clusters at 8-10% through the early 2030s. North America captures roughly 38% of global revenue; Asia-Pacific grows fastest at ~7% CAGR on cost-advantaged capacity.

Segmentation by Modality

Segment	2026 Est.	CAGR	Notes
Small Molecule API & DP	~$110-130B	5-7%	Largest segment by volume; mature
Biologic Drug Substance	~$35-45B	10-12%	Monoclonal antibodies, bispecifics, ADCs
Biologic Fill-Finish	~$18-24B	12-15%	Capacity-constrained; GLP-1 demand absorbing
Cell & Gene Therapy	~$5-7B (2025)	18-19%	Projected to $29B by 2035
Packaging & Labeling	~$25-30B	6-8%	Cold chain sub-segment growing fastest
Analytical & Clinical Supply	~$15-20B	8-10%	Release testing, stability, trial logistics

Growth Drivers

1. Biotech outsourcing dependency. More than 80% of biotechs use CDMO partners for at least one step of manufacturing. Small and mid-cap biotechs rarely build in-house commercial facilities; venture economics favor asset-light models.
2. GLP-1 injectable demand. Novo Nordisk and Eli Lilly have run sustained sterile fill-finish shortages since 2023. The Novo-Catalent acquisition (closed December 2024) internalized three fill-finish sites worth roughly $11B of Catalent’s network.
3. Cell and gene therapy pipeline. Over 2,000 CGT assets are in clinical development. CGT CDMO demand has outrun capacity since 2022.
4. BIOSECURE Act reshoring. Biopharma RFPs began steering away from WuXi and other Chinese providers in 2024, even before the law passed in December 2025.
5. Pipeline complexity. Bispecifics, ADCs, peptides, and targeted protein degraders require specialized capabilities that only a subset of CDMOs have built.

The Big CDMO Tiers

Mega-CDMOs ($3B+ CDMO Revenue)

Company	HQ	Est. CDMO Revenue	Modality Strength	BIOSECURE Exposure
Lonza	Switzerland	~$7.5B (2024)	Biologics DS, CGT, mammalian + microbial, bioconjugates	Low
Catalent (Novo Holdings)	US	~$4.2B	Fill-finish, oral solids, biologics; three sites moved to Novo Nordisk	Low
Samsung Biologics	South Korea	~$3.2B	Biologics DS (mAb-heavy); Songdo 1-5 plants	Low
Thermo Fisher Patheon	US	~$3.5B pharma services	Sterile injectables, biologics DS, viral vectors (Brammer)	Low
WuXi Biologics	China	~$2.8B	Biologics DS/DP, bioconjugates	High
Fujifilm Diosynth	Japan/US/UK/DK	~$2-2.5B	Biologics DS (mammalian + microbial), viral vectors, CGT	Low

Lonza’s 2024-2025 performance stands out: H1 2025 sales grew 19% at constant currencies to 3.6B Swiss francs, with the core CDMO business up ~23%. Samsung Biologics delivered 20%+ revenue growth in 2024 and guided 20%+ for 2025.

Tier 2 ($500M-$3B)

Company	Notes
Boehringer Ingelheim BioXcellence	Biologics DS; captive + third-party capacity
AGC Biologics	Biologics DS; Copenhagen, Boulder, Seattle, Milan, Chiba sites
Charles River Laboratories	CGT cell banking, viral vectors, testing; Cobra Biologics integration
Recipharm	Oral, injectable, inhalation; PE-owned (EQT)
Siegfried	Small molecule API, sterile fill-finish
Pfizer CentreOne	Sterile injectables, steroids, OSD leveraging Pfizer’s commercial sites
Piramal Pharma Solutions	API, ADC, injectables
Ajinomoto Bio-Pharma	Peptides, complex actives

Cell & Gene Therapy Specialists

Autologous CAR-T, allogeneic cell therapies, and in-vivo gene therapies (AAV, lentivirus) require dedicated GMP suites, viral vector production, and cryogenic logistics. Key players:

• Lonza Cell & Gene, Portsmouth NH, Houston TX, Geleen NL, Singapore; expanded US capacity February 2025 to support late-stage and commercial CGT programs.
• Catalent Cell & Gene, Harmans MD, Gosselies BE; upgraded viral vector capabilities January 2025.
• Thermo Fisher (Brammer Bio), Lexington MA, Cambridge MA; acquired for $1.7B in 2019 and integrated into Patheon.
• National Resilience, Multi-site US build-out announced $225M fill-finish expansion citing GLP-1 demand; CGT and biologics coverage.
• Fujifilm Diosynth, College Station TX, RTP NC, Teesside UK; major viral vector investments.
• WuXi ATU (now Altaris), WuXi AppTec sold US and UK cell therapy operations to Altaris in early 2025; Oxgene (UK) acquired by WuXi in 2021 moved with that divestiture. Oxford Biomedica operates independently in the UK as a viral vector specialist with partnerships including Novartis.

Sterile Fill-Finish Specialists

Fill-finish is the single most capacity-constrained step in biopharma manufacturing. Named specialists:

• Grand River Aseptic Manufacturing (GRAM), Grand Rapids MI; sterile injectables for biologics and small molecules.
• Baxter BioPharma Solutions, Bloomington IN, Halle DE; legacy sterile filler.
• BioSpectra, Bangor PA; buffers, excipients, sterile services.
• Emergent BioSolutions CDMO, Baltimore MD; sterile fill-finish (reorganized post-COVID).
• Pfizer CentreOne, Catalent, Thermo Fisher Patheon, all offer significant sterile capacity as well.

GLP-1 Manufacturing

GLP-1 peptide-based obesity and diabetes therapies (semaglutide, tirzepatide) created the largest single-drug-class manufacturing buildout in industry history:

• Novo Nordisk, Acquired three Catalent fill-finish sites (Bloomington IN, Brussels BE, Anagni IT) for ~$11B inside the Novo Holdings Catalent transaction; multi-billion expansion in Kalundborg DK and Clayton NC.
• Eli Lilly, $23B+ committed to new US and European capacity (Lebanon IN, Concord NC, Limerick IE, Alzey DE) since 2020.
• Compounding pharmacies, Filled semaglutide and tirzepatide during FDA shortage declarations; FDA removed tirzepatide from the shortage list October 2024 and semaglutide February 2025, creating legal and regulatory risk for continued compounding.

Competitive Comparison

CDMO	Core Modality	Commercial Scale	FDA Inspection Track Record	BIOSECURE Exposure	Best For
Lonza	Biologics DS, CGT	Very high	Strong; multi-site cGMP	Low	Biologics launch + CGT at scale
Catalent (Novo)	Fill-finish, oral, biologics	Very high	Mixed history (historical 483s at Brussels, Bloomington); remediated	Low	Complex DP + fill-finish (note Novo priority)
Samsung Biologics	Biologics DS (mAb)	Very high	Strong	Low	Monoclonal antibody DS at commercial scale
Thermo Fisher Patheon	Sterile, biologics, viral vectors	High	Strong across 60+ sites	Low	Integrated DS/DP/CGT
WuXi Biologics	Biologics DS/DP	High	Strong technically	High	Non-US-funded programs (risk)
Fujifilm Diosynth	Biologics DS, viral vectors	Medium-high	Strong	Low	Microbial + mammalian + CGT
Boehringer BioXcellence	Biologics DS	Medium-high	Strong	Low	mAb and complex biologics
AGC Biologics	Biologics DS	Medium	Strong	Low	Mid-size mAb programs
National Resilience	Biologics, CGT, fill-finish	Medium (ramping)	New-build; limited track record	Low	US-domestic capacity for reshoring
Oxford Biomedica	Viral vectors (lentivirus)	Medium	Strong in Europe	Low	Lentiviral vector for CGT

FDA inspection notes are directional and change quarterly; verify current status via the FDA Inspection Classification Database before committing supply.

BIOSECURE Act and China Exposure

2026 Status

The BIOSECURE Act was signed into law on December 18, 2025 as part of the FY2026 National Defense Authorization Act. The law prohibits federal agencies from contracting with, and federally funded firms from using, designated biotechnology companies of concern (BCCs). A five-year transition period runs through 2030.

Initial designations: BGI Group and MGI Tech (genomics companies) are named via the underlying Defense Department 1260H list that the Act references.

WuXi companies: As of early 2026, WuXi AppTec, WuXi Biologics, and WuXi XDC have NOT been formally designated. However, on December 18, 2025 the chairs of multiple Senate and House committees sent a letter to the Department of Defense recommending their addition to the next 1260H update. Industry lawyers assume designation is likely during 2026-2027.

The De Facto BIOSECURE Effect

Western biopharma already began diversifying away from Chinese CDMOs in 2024-2025 ahead of formal designation:

• WuXi Biologics agreed to sell its Ireland vaccine site to Merck for ~$521M in early 2025.
• WuXi AppTec divested US and UK operations of WuXi ATU to Altaris in February-March 2025.
• Multiple biotechs added dual-source clauses to existing WuXi contracts.

The reshoring wave has tightened non-Chinese fill-finish, viral vector, and mammalian biologics capacity at the same time that GLP-1 demand is absorbing sterile slots.

What Launch Teams Should Do

1. Audit current supplier footprint. Identify any Chinese-designated or likely-designated entities in the drug substance, drug product, packaging, or testing chain.
2. Model 2030 transition. The five-year window requires tech transfer, process validation, and regulatory filing amendments. Budget $5-15M per tech transfer for biologics; $15-40M+ for CGT.
3. Book Western capacity early. Lonza, Samsung, Fujifilm, Thermo Fisher, AGC, and Boehringer report 2026-2028 slots filling on biologics DS.
4. Track 1260H list updates. The Defense Department updates the list periodically; new designations become effective for new contracts immediately.

Cell and Gene Therapy CDMO Capacity

Market Size and Trajectory

The CGT CDMO segment was valued at roughly $5.2B in 2025 and is projected to reach $29.5B by 2035 (~18.9% CAGR), per industry research. Capacity expansion cannot match demand growth in the near term.

Manufacturing Modality Split

Modality	Process	Lead Time	Typical Cost
Autologous cell therapy (e.g., CAR-T)	Patient cells processed per dose	2-6 weeks vein-to-vein	$100K-$1M+ per batch
Allogeneic cell therapy	Donor-derived, batch-produced	Scheduled per campaign	$50K-$500K per batch
In-vivo gene therapy (AAV, LV)	Viral vector manufacture then dose	12-24 month campaign cycle	Bespoke; $5M-$50M+ per batch

Named Capacity

• Lonza, Portsmouth NH (cell therapy), Houston TX (viral vector), Geleen NL (cell therapy), Singapore. Expanded US CGT capacity February 2025 for late-stage and commercial programs.
• Catalent Cell & Gene, Harmans MD (viral vector and cell therapy); Gosselies BE.
• Thermo Fisher (Brammer Bio), Lexington/Cambridge MA; viral vector manufacturing suites.
• Fujifilm Diosynth, College Station TX, Teesside UK; major viral vector investments.
• National Resilience, Multi-site US network; biologics + CGT + fill-finish; has announced $1.5B+ in cumulative capacity investments.
• Oxford Biomedica, Oxford UK; lentiviral vector specialist with a long-running Novartis Kymriah relationship.
• Charles River Laboratories, Cobra Biologics integration for viral vectors and plasmid DNA.

Pricing Dynamics

CGT manufacturing is bespoke and volatile. Directional pricing:

• Autologous CAR-T cGMP batch: $100K-$300K+ per dose at commercial scale (captive economics, e.g., Kite at Gilead, are lower than outsourced).
• AAV viral vector cGMP lot: $5M-$15M per lot at 200L-2,000L scale; $20M+ for high-volume pivotal programs.
• Lentiviral vector cGMP lot: $3M-$10M per lot.
• Plasmid DNA cGMP: $1M-$3M per lot.

All ranges are directional and change with scale, potency, yield, and CDMO capacity utilization. Treat any CGT quote as a starting point for multi-round negotiation.

Sterile Fill-Finish Landscape

Sterile fill-finish is the step where bulk drug substance is formulated, filled into vials or prefilled syringes or cartridges, lyophilized if needed, inspected, and packaged. It is the most capacity-constrained, regulatorily sensitive, and capex-intensive step in biologics manufacturing.

Capacity Status 2026

Industry trackers estimate 12-15 major fill-finish investments totaling $1.5B-$2B coming online in 2024-2026, easing but not eliminating the capacity crunch. Key dynamics:

• GLP-1 absorption. Novo Nordisk and Lilly between them have captured fill-finish slots equivalent to double-digit percentages of global prefilled syringe capacity.
• High-concentration biologics demand. Modern mAbs and bispecifics require specialized handling (viscosity, aggregation, visible particulate inspection).
• Single-use vs. stainless steel trade-off. Single-use lines enable faster changeover but cap batch size; stainless steel is cheaper at scale but slower to reconfigure.

FDA 483 Patterns

Regulatory enforcement at fill-finish sites commonly cites:

• Environmental monitoring (EM) gaps and incomplete trending.
• Aseptic media fill failures and investigation adequacy.
• Particulate inspection process control.
• Out-of-specification (OOS) investigation rigor.
• Change control for equipment or procedures.

Repeated warning letters at any single site should be a red flag in CDMO selection; prior warning letters that have been remediated (EIR closed without action) are common and typically acceptable.

CDMO Selection Framework

A structured CDMO RFP for a launch program should score vendors across six dimensions.

1. Modality Fit

API vs. drug substance vs. drug product vs. fill-finish vs. CGT are distinct capabilities. A CDMO that excels at small molecule API synthesis is rarely the right partner for bispecific antibody drug substance. Confirm the specific platform, equipment, and expertise.

2. Scale Readiness

Phase 1 supply (1-5 kg biologic DS, 10K-50K vials) is vastly different from commercial (50-500 kg DS, 1M+ vials annually). Tech transfer from a clinical-scale CDMO to a commercial-scale CDMO mid-development costs $5-15M per biologic program and 12-24 months. Biotech teams that start with a clinical-only CDMO and plan to transfer later frequently encounter launch timing slip.

3. Regulatory Track Record

Pull the FDA Inspection Classification Database for the specific site. Review EMA inspection outcomes. Check recent BLA or NDA filings on the CDMO’s client list. A CDMO with a clean pre-approval inspection (PAI) at the specific site is worth a premium.

4. Capacity Availability

Fill-finish, viral vector, and high-concentration biologic DS slots are booked 18-36 months out in 2026. Do not sign a term sheet without a binding capacity commitment for the commercial launch window. Include pricing protection for the first 2-3 years of commercial supply.

5. Geographic and Geopolitical Fit

BIOSECURE Act risk, tariff exposure, FDA inspection complexity for international sites, and proximity to key markets all matter. A US-based launch targeting a 2028 approval should prioritize US or allied-country (EU, Japan, Switzerland, Korea) manufacturing.

6. Tech Transfer and Commercial Terms

Minimum order quantities (MOQs), take-or-pay commitments, exclusivity clauses, and tech transfer assistance costs can materially change the economics. Favor CDMOs with transparent cost structures and clear exit provisions. Beware of IP grants that could entangle your molecule in the CDMO’s platform patents.

Pricing Dynamics

All pricing below is directional, highly variable by scale, and should be treated as starting points for negotiation.

Service	Price Range	Notes
Biologic DS (mAb, 2,000L batch)	$5K-$50K per gram	Per-batch: $500K-$5M depending on titer and purity
Small molecule API (commercial kg)	$500-$10K per kg	Highly scale-dependent
Sterile fill-finish (vial)	$2-$20 per vial	Low for simple mAb; high for complex biologic + lyo
Sterile fill-finish (PFS)	$3-$25 per prefilled syringe	Device assembly adds cost
Viral vector cGMP lot	$5M-$20M+	AAV, LV; 200L-2,000L scale
Autologous cell therapy	$100K-$300K+ per patient	Outsourced; captive is lower
Tech transfer (biologic)	$5M-$15M	12-24 months
Tech transfer (CGT)	$15M-$40M+	Highly variable

The BIOSECURE-Driven Reshoring Wave

The combination of BIOSECURE reshoring, GLP-1 fill-finish absorption, and CGT pipeline growth is producing the first sustained CDMO capacity shortage in over a decade.

2024-2026 Capacity Additions (US/Europe)

• Lilly, Lebanon IN, Concord NC, Limerick IE, Alzey DE; $23B+ committed since 2020.
• Novo Nordisk, Kalundborg DK expansion + three Catalent sites internalized; Clayton NC.
• Lonza, Visp CH and Vacaville CA biologics expansion; US CGT February 2025.
• Samsung Biologics, Songdo Plant 5 commercial start; further plant 6+ planning.
• Resilience, Announced $225M fill-finish expansion citing GLP-1 demand.
• Fujifilm Diosynth, $1.6B expansion at RTP NC (microbial + mammalian).
• Catalent (Novo Holdings), Continued investment in non-Novo client fill-finish capacity at remaining sites.

Implications for Launch Teams

1. Book capacity early. 2027-2028 commercial launches should have binding capacity agreements in place by mid-2026.
2. Price will reflect scarcity. Fill-finish per-unit costs are up 15-30% since 2022 on constrained capacity; expect further firming in 2026-2027.
3. Dual-sourcing is back on the table. Post-COVID and post-BIOSECURE, dual-source manufacturing is moving from “nice to have” to standard for commercial-stage assets.
4. Tech transfer costs should be budgeted. A program that assumes zero tech transfer between clinical and commercial scale is underfunded.

Bottom Line

The 2026 CDMO market is expanding, consolidating, and reshoring simultaneously. Launch teams face a narrower set of credible Western partners at a moment when GLP-1 and CGT demand are compressing available slots. Modality fit, regulatory track record, and binding capacity commitments matter more than headline price.

Start CDMO selection 24-36 months before the commercial launch window. Treat BIOSECURE exposure as a binary screen for any federally funded program. Assume tech transfer is required somewhere in the lifecycle and budget for it.

For adjacent coverage:

• Cell & Gene Therapy Commercialization Services for the downstream commercial layer.
• Rare Disease Launch Vendor Playbook for vendor stack around low-volume biologics.
• Pharma Services Market Sizing for the broader services TAM context.
• Hub Services Market Analysis for the patient-facing layer downstream of manufacturing.
• Pharma Services Explained for a category primer.

Cold chain packaging vendors on Rx Almanac include Cold Chain Technologies, Csafe, ThermoSafe, Aerosafe Global, and Cryopak; distributor-affiliated manufacturing and 3PL coverage includes Cardinal Health.

---

Sources: Fierce Pharma, BioPharma Dive, Contract Pharma, DCAT Value Chain Insights, PharmaSource, company press releases (Novo Holdings, Catalent, Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher), FDA Inspection Classification Database, and published market research from Precedence Research, Fortune Business Insights, Mordor Intelligence, Towards Healthcare, and MarketsandMarkets. Market size figures are author-synthesized from multiple public sources and represent ranges rather than point estimates. Pricing figures are directional, based on industry practitioner reports, and should not be relied on for procurement decisions without current vendor quotes. The BIOSECURE Act designation status reflects publicly reported legislative and Defense Department activity as of early 2026 and is subject to change.